Remicade Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Remicade (infliximab) is a biologic drug classified as a tumor necrosis factor-alpha (TNF-a) inhibitor. It is used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, a protein that plays a key role in inflammation, Remicade helps alleviate symptoms, prevent disease progression, and enhance the quality of life.

The primary disease indications for Remicade include Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that often results in symptoms like abdominal pain, severe diarrhea, weight loss, and fatigue. The medication can be administered via subcutaneous, intravenous, or parenteral routes, and is used in settings such as hospitals, clinics, ambulatory care, and home care.

Tariffs are impacting the remicade market by increasing costs related to imported monoclonal antibody manufacturing equipment, active pharmaceutical ingredients, cold-chain logistics, and sterile delivery systems. Hospitals and specialty clinics in North America and Europe are most affected due to biologics import dependency, while Asia-Pacific experiences supply chain cost pressures. These tariffs elevate therapy costs and influence reimbursement dynamics. However, they are also encouraging localized biologics production, regional biosimilar development, and strengthened domestic pharmaceutical manufacturing capabilities.

The remicade market research report is one of a series of new reports from The Business Research Company that provides remicade market statistics, including remicade industry global market size, regional shares, competitors with a remicade market share, detailed remicade market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. This remicade market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade market size has grown strongly in recent years. It will grow from $2656.87 million in 2025 to $2803.31 million in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, wider clinical acceptance of biologics, expansion of hospital infusion centers, improved diagnosis of inflammatory diseases, growth in specialty pharmaceutical distribution.

The remicade market size is expected to see strong growth in the next few years. It will grow to $3433.68 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for biosimilar competition, rising investments in biologics manufacturing, expansion of home infusion care models, growing focus on personalized autoimmune therapies, advancements in monoclonal antibody development. Major trends in the forecast period include increasing use of tnf-alpha inhibitor therapies, rising adoption of biologic treatments for autoimmune diseases, growing preference for long-term disease control drugs, expansion of specialty infusion services, enhanced focus on patient-centered treatment outcomes.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the Remicade market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, tissues, or organs, treating them as foreign invaders. The rise in autoimmune diseases is attributed to a mix of genetic factors, environmental changes, greater exposure to pollutants, lifestyle choices, and enhanced diagnostic awareness. Remicade (infliximab) is used to manage these diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-a), a key inflammatory cytokine involved in conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis. For example, in April 2025, GOV.UK, a UK-based public health agency, reported that in 2024, 17.9% of individuals aged 16 and over self-reported a long-term musculoskeletal (MSK) condition, with a higher incidence in females (20.0%) compared to males (15.6%). Therefore, the rising incidence of autoimmune diseases is a driving force behind the growth of the Remicade market.

Leading companies in the Remicade (infliximab) market are focusing on developing innovative solutions, such as subcutaneous formulations of biologic therapies, to meet the growing demand for improved patient convenience, better treatment adherence, and more time-efficient alternatives to traditional intravenous dosing. Subcutaneous biologics allow patients to self-administer maintenance doses at home, reducing the need for infusion-center visits and offering a more accessible option compared to conventional IV formulations. For example, in March 2024, Celltrion USA, Inc., a US-based biopharmaceutical company, launched Zymfentra (infliximab-dyyb), the first FDA-approved subcutaneous formulation of infliximab. Zymfentra is indicated as maintenance therapy for adults with moderate-to-severe active ulcerative colitis (UC) and Crohn's disease (CD), which are part of inflammatory bowel disease (IBD). Approved for use after IV induction with an infliximab product, Zymfentra offers a convenient, self-administered alternative for long-term disease management.

In September 2024, Tharimmune Inc., a US-based biopharmaceutical company, acquired a global license from Intract Pharma for an undisclosed amount. This acquisition aims to develop an oral version of infliximab, which has traditionally been administered intravenously, thereby improving patient compliance and potentially lowering healthcare costs related to long-term intravenous therapy. Intract Pharma Ltd. is a UK-based provider of infliximab.

Major companies operating in the remicade market are Janssen Biotech Inc.

North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remicade market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the remicade market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses remicade market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The remicade market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Indication: Crohn's disease; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Ulcerative Colitis; Plaque psoriasis
• 2) By Route Of Administration: Subcutaneous; Intravenous; Parenteral
• 3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
• Companies Mentioned: Janssen Biotech Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.